Phase II evaluation of merbarone in renal cell carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1994-06

AUTHORS

Robert C. Flanigan, Joseph H. Saiers, Michael Wolf, Eric H. Kraut, Anthony Y. Smith, Brent Blumenstein, E. David Crawford

ABSTRACT

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1-5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1-15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma. More... »

PAGES

147-149

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00874446

DOI

http://dx.doi.org/10.1007/bf00874446

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043297360

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7860233


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiobarbiturates", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Loyola University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.411451.4", 
          "name": [
            "Loyola University Medical Center, Maywood, Illinois"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flanigan", 
        "givenName": "Robert C.", 
        "id": "sg:person.01310214203.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310214203.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Albuquerque VAMC, Albuquerque, New Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saiers", 
        "givenName": "Joseph H.", 
        "id": "sg:person.0636145673.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636145673.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, Seattle, Washington"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolf", 
        "givenName": "Michael", 
        "id": "sg:person.01225644344.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225644344.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ohio State University", 
          "id": "https://www.grid.ac/institutes/grid.261331.4", 
          "name": [
            "Ohio State University, Columbus, Ohio"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraut", 
        "givenName": "Eric H.", 
        "id": "sg:person.01012674343.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012674343.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of New Mexico", 
          "id": "https://www.grid.ac/institutes/grid.266832.b", 
          "name": [
            "University of New Mexico School of Medicine, Albuquerque, New Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Anthony Y.", 
        "id": "sg:person.01133360500.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133360500.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Southwest Oncology Group Statistical Center, Seattle, Washington"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blumenstein", 
        "givenName": "Brent", 
        "id": "sg:person.01255417036.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255417036.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Colorado Denver", 
          "id": "https://www.grid.ac/institutes/grid.241116.1", 
          "name": [
            "University of Colorado, Denver, Colorado, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crawford", 
        "givenName": "E. David", 
        "id": "sg:person.01261331436.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261331436.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0006-2952(85)90368-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040536350"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(85)90368-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040536350"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079002940", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1994-06", 
    "datePublishedReg": "1994-06-01", 
    "description": "The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1-5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1-15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00874446", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "name": "Phase II evaluation of merbarone in renal cell carcinoma", 
    "pagination": "147-149", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ce3dcdcebe1882c679dc37ce127f375df9bf19a9913b0f3f58108e0a94f75854"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7860233"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00874446"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043297360"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00874446", 
      "https://app.dimensions.ai/details/publication/pub.1043297360"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000482.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00874446"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00874446'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00874446'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00874446'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00874446'


 

This table displays all metadata directly associated to this object as RDF triples.

158 TRIPLES      21 PREDICATES      38 URIs      28 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00874446 schema:about N101968dccfe44f78af80df4f0f493231
2 N3606872a903c45c780671e89326fe344
3 N3d3a8d0d55fb42bb82c2a9f59ba3185b
4 N70306568535d4f3582dc695505f58d89
5 N7d1a0abcd3b547268b8949814cf914d1
6 Nee8e4640b7a842adb1e6ba80ed91a2a5
7 Nf9c257abeb174b5ea6981879a0504022
8 anzsrc-for:11
9 anzsrc-for:1103
10 schema:author N862864b8439f4efb9ff25e5bb35c6981
11 schema:citation https://app.dimensions.ai/details/publication/pub.1079002940
12 https://doi.org/10.1016/0006-2952(85)90368-5
13 schema:datePublished 1994-06
14 schema:datePublishedReg 1994-06-01
15 schema:description The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1-5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1-15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma.
16 schema:genre research_article
17 schema:inLanguage en
18 schema:isAccessibleForFree false
19 schema:isPartOf N6178a98a1b0c42539b1a712de13bc9e8
20 N7797642c89a448fb99e3ec5f8e284959
21 sg:journal.1094201
22 schema:name Phase II evaluation of merbarone in renal cell carcinoma
23 schema:pagination 147-149
24 schema:productId N4fc94ba41fd343e884ba07c324ae1888
25 N59e940e7cfe8462a97df515e943e9525
26 N6801c0d3338c4c11acc642cb51da041a
27 Na7eb8d1e1aa64218ac452912a6a56c66
28 Nd624cdfef987410ba3f0bba6ea21e7df
29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043297360
30 https://doi.org/10.1007/bf00874446
31 schema:sdDatePublished 2019-04-10T15:44
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher Ned2a4b1920ca4b499027f7ccb8ff7755
34 schema:url http://link.springer.com/10.1007/BF00874446
35 sgo:license sg:explorer/license/
36 sgo:sdDataset articles
37 rdf:type schema:ScholarlyArticle
38 N07e36659b2c7488785aa8c0a21a8a40d rdf:first sg:person.01225644344.61
39 rdf:rest N973a9455069a427aa2c15c6d79bb589d
40 N101968dccfe44f78af80df4f0f493231 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
41 schema:name Thiobarbiturates
42 rdf:type schema:DefinedTerm
43 N247ca85e92b8474787c11902af372749 rdf:first sg:person.0636145673.70
44 rdf:rest N07e36659b2c7488785aa8c0a21a8a40d
45 N251383b3de5a48d9a2f3806cbd34176f rdf:first sg:person.01133360500.72
46 rdf:rest N46f1a7c0841c418cb1a5c31b2483cd66
47 N3606872a903c45c780671e89326fe344 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
48 schema:name Infusions, Intravenous
49 rdf:type schema:DefinedTerm
50 N3d3a8d0d55fb42bb82c2a9f59ba3185b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
51 schema:name Humans
52 rdf:type schema:DefinedTerm
53 N46f1a7c0841c418cb1a5c31b2483cd66 rdf:first sg:person.01255417036.55
54 rdf:rest N56d96a2310a64138a897d20b3022049d
55 N4fc94ba41fd343e884ba07c324ae1888 schema:name doi
56 schema:value 10.1007/bf00874446
57 rdf:type schema:PropertyValue
58 N56d96a2310a64138a897d20b3022049d rdf:first sg:person.01261331436.43
59 rdf:rest rdf:nil
60 N59e940e7cfe8462a97df515e943e9525 schema:name pubmed_id
61 schema:value 7860233
62 rdf:type schema:PropertyValue
63 N6178a98a1b0c42539b1a712de13bc9e8 schema:volumeNumber 12
64 rdf:type schema:PublicationVolume
65 N6801c0d3338c4c11acc642cb51da041a schema:name dimensions_id
66 schema:value pub.1043297360
67 rdf:type schema:PropertyValue
68 N70306568535d4f3582dc695505f58d89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Kidney Neoplasms
70 rdf:type schema:DefinedTerm
71 N7797642c89a448fb99e3ec5f8e284959 schema:issueNumber 2
72 rdf:type schema:PublicationIssue
73 N7d1a0abcd3b547268b8949814cf914d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Drug Administration Schedule
75 rdf:type schema:DefinedTerm
76 N85dcdd7992964beb984910819685b05c schema:name Albuquerque VAMC, Albuquerque, New Mexico
77 rdf:type schema:Organization
78 N862864b8439f4efb9ff25e5bb35c6981 rdf:first sg:person.01310214203.32
79 rdf:rest N247ca85e92b8474787c11902af372749
80 N973a9455069a427aa2c15c6d79bb589d rdf:first sg:person.01012674343.62
81 rdf:rest N251383b3de5a48d9a2f3806cbd34176f
82 Na7eb8d1e1aa64218ac452912a6a56c66 schema:name readcube_id
83 schema:value ce3dcdcebe1882c679dc37ce127f375df9bf19a9913b0f3f58108e0a94f75854
84 rdf:type schema:PropertyValue
85 Nd624cdfef987410ba3f0bba6ea21e7df schema:name nlm_unique_id
86 schema:value 8309330
87 rdf:type schema:PropertyValue
88 Ned2a4b1920ca4b499027f7ccb8ff7755 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 Nee8e4640b7a842adb1e6ba80ed91a2a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antineoplastic Agents
92 rdf:type schema:DefinedTerm
93 Nf9c257abeb174b5ea6981879a0504022 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Carcinoma, Renal Cell
95 rdf:type schema:DefinedTerm
96 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
97 schema:name Medical and Health Sciences
98 rdf:type schema:DefinedTerm
99 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
100 schema:name Clinical Sciences
101 rdf:type schema:DefinedTerm
102 sg:journal.1094201 schema:issn 0167-6997
103 1573-0646
104 schema:name Investigational New Drugs
105 rdf:type schema:Periodical
106 sg:person.01012674343.62 schema:affiliation https://www.grid.ac/institutes/grid.261331.4
107 schema:familyName Kraut
108 schema:givenName Eric H.
109 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012674343.62
110 rdf:type schema:Person
111 sg:person.01133360500.72 schema:affiliation https://www.grid.ac/institutes/grid.266832.b
112 schema:familyName Smith
113 schema:givenName Anthony Y.
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133360500.72
115 rdf:type schema:Person
116 sg:person.01225644344.61 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
117 schema:familyName Wolf
118 schema:givenName Michael
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225644344.61
120 rdf:type schema:Person
121 sg:person.01255417036.55 schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
122 schema:familyName Blumenstein
123 schema:givenName Brent
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255417036.55
125 rdf:type schema:Person
126 sg:person.01261331436.43 schema:affiliation https://www.grid.ac/institutes/grid.241116.1
127 schema:familyName Crawford
128 schema:givenName E. David
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261331436.43
130 rdf:type schema:Person
131 sg:person.01310214203.32 schema:affiliation https://www.grid.ac/institutes/grid.411451.4
132 schema:familyName Flanigan
133 schema:givenName Robert C.
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310214203.32
135 rdf:type schema:Person
136 sg:person.0636145673.70 schema:affiliation N85dcdd7992964beb984910819685b05c
137 schema:familyName Saiers
138 schema:givenName Joseph H.
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636145673.70
140 rdf:type schema:Person
141 https://app.dimensions.ai/details/publication/pub.1079002940 schema:CreativeWork
142 https://doi.org/10.1016/0006-2952(85)90368-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040536350
143 rdf:type schema:CreativeWork
144 https://www.grid.ac/institutes/grid.241116.1 schema:alternateName University of Colorado Denver
145 schema:name University of Colorado, Denver, Colorado, USA
146 rdf:type schema:Organization
147 https://www.grid.ac/institutes/grid.261331.4 schema:alternateName The Ohio State University
148 schema:name Ohio State University, Columbus, Ohio
149 rdf:type schema:Organization
150 https://www.grid.ac/institutes/grid.266832.b schema:alternateName University of New Mexico
151 schema:name University of New Mexico School of Medicine, Albuquerque, New Mexico
152 rdf:type schema:Organization
153 https://www.grid.ac/institutes/grid.411451.4 schema:alternateName Loyola University Medical Center
154 schema:name Loyola University Medical Center, Maywood, Illinois
155 rdf:type schema:Organization
156 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
157 schema:name Southwest Oncology Group Statistical Center, Seattle, Washington
158 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...